TY - JOUR
AB - Inpharma 1220 - 15 Jan 2000 Fluticasone propionate better value than flunisolide in asthma Fluticasone propionate is more cost effective than flunisolide in the management of corticosteroid-naive patients with moderate asthma, say German investigators. They conducted a retrospective economic analysis comparing the 2 treatments from the perspective of a third-party payer using data for 744 patients (mean age 49 years) who participated in two randomised trials in Germany. On an intention-to-treat basis, 401 and 343 patients participating in an open-label and double-blind trial, respectively, were randomised to receive via a metered- dose inhaler either fluticasone propionate 250µg twice daily or flunisolide 500µg twice daily for 6 and 8 weeks, respectively. The investigators report that the mean increases in morning and evening peak expiratory flow rate were significantly greater in fluticasone propionate than flunisolide recipients in both studies. The number of successfully treated patients and the proportion of symptom-free days were also substantially higher in the fluticasone propionate groups. In the economic analysis, both the cost per successfully treated patient per day and the cost per symptom-free day were lower for the fluticasone propionate group than the flunisolide group. The marginal cost of the improved efficacy gained with fluticasone propionate 
TI - Fluticasone propionate better value than flunisolide in asthma
JF - Inpharma Weekly
DO - 10.2165/00128413-200012200-00012
DA - 2013-02-09
UR - https://www.deepdyve.com/lp/springer-journals/fluticasone-propionate-better-value-than-flunisolide-in-asthma-0TtNBsGARL
SP - 7
EP - 7
VL - 1220
IS - 1
DP - DeepDyve
ER -